Source comparison
PT-141 Dosage Female Arousal 2026: Research Grade vs Clinical Product Comparison
Dosage Precision Fixed 1.75mg auto-injector. No titration flexibility Lyophilized powder allows 0.1mg dosing increments for individualized protocols Prepared at specified concentration by 503B facilities. Typically 1.0mg/mL or 2.0mg/mL allowing flexible dosing
This comparison does not assign a generated winner or score.
- Dosage Precision
- Fixed 1.75mg auto-injector. No titration flexibility
- Lyophilized powder allows 0.1mg dosing increments for individualized protocols
- Prepared at specified concentration by 503B facilities. Typically 1.0mg/mL or 2.0mg/mL allowing flexible dosing
- Research-grade and compounded options enable the dose titration necessary for optimizing individual response while minimizing side effects
- Cost Per Dose
- $800–$950 per injection (list price)
- $45–$85 per dose at 1.75mg equivalent (bulk synthesis pricing)
- $120–$180 per dose through licensed telehealth platforms
- The 10–20× cost differential between branded product and research-grade material represents regulatory approval overhead, not purity or efficacy differences
- Purity Verification
- USP-grade, batch-tested to >98% purity with CoA
- Third-party HPLC verification available. Reputable suppliers provide >97% purity with <3% acetate salt
- USP 797/800 compliant compounding under state board oversight. Purity typically 95–98%
- Purity differences between FDA-approved and research-grade are clinically irrelevant. The 1–2% gap doesn't affect receptor binding or downstream signaling
- Regulatory Status
- FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women
- Not approved for human use. Legal for research purposes under proper institutional oversight
- Legal when prescribed by licensed physician under state medical practice acts
- Regulatory status reflects approval pathway completion, not safety or efficacy profile. The active molecule is identical across all three categories